6 Acquisition International - Issue 5 2022 Mar22405 Most Innovative Defibrillator Device Developer 2022 - USA Nearly 7 million people die of sudden cardiac arrest (SCA) each year. These are people who are not in the hospital – they are ordinary people out doing ordinary things. They are asymptomatic and otherwise healthy. Upon onset, if the victim of SCA does not receive a life-saving shock with a defibrillator in three to four minutes, they will die. Time is of the essence, and CardioThrive Inc’s mission is to make SCA a routinely survivable event. ardioThrive founder and CEO, Shelley Savage’s ex-husband is a cardiologist and a bicyclist. He’s been on many group rides and seen many people fall over while riding, sadly stricken with sudden cardiac arrest. Even though he is highly skilled and highly trained to treat SCA, he didn’t have the tool he needed to save someone’s life. Automatic external defibrillators (AEDs) are mounted on the wall in many public places, but they’re still too large to carry in your pocket or bag. You also have to assemble them before use, that is, you have to unwrap the electrode pads, plug them in, read directions about how to use the device, and know where to place the pads on the victim’s chest. For an untrained bystander, this is extremely intimidating, which is why people won’t use them. This is the reason for the abysmal less than 1% survival rate for public access AEDs. CardioThrive’s approach to solving that problem was to design an ultra-portable, single-use, fully automatic AED which requires no assembly before use. It’s so intuitive to use that even a small child could use it and deliver a life-saving shock in under 20 seconds. There’s nothing else quite like it in the world of AEDs. CardioThrive’s business model is two-fold. First, it sells its units to hospitals. There are 78,000 “code blues” called in US hospitals each and every day. Nearly 287,000 people die in hospitals of cardiac arrest each year. Right now, there is one crash cart with one defibrillator per every seven beds. If two patients happen to code at the same time, the hospital staff are forced to make the unfortunate decision as to who lives and who dies – and this happens more than you think. If CardioThrive’s PocketDefib was mounted on the wall next to every bed, every patient would receive a life-saving shock immediately and many more lives would be saved. CardioThrive’s device is fully automatic and will even record the cardiac event. The hospital staff can scan the barcode on the device which instantly uploads it to the hospital’s medical record system and the cardiac event becomes part of the patient’s medical record. After that, they simply toss the device in a recycle bin. CardioThrive will collect the bin and refurbish the units by replacing the batteries and electrode pads, reset the software, as well as clean, sterilise and repackage them so they can be leased to the general public for $100 per month with all maintenance for the device included. Since 70% of all out-of-hospital SCA events occur in the home, there is a large number of people who need to have access to an AED. AEDs are available to the public for purchase, but the upfront cost is $1,300-$3,200, plus ongoing maintenance and replacement C parts costs. This is cost prohibitive for most people, so CardioThrive’s contract, month-tomonth programme gives access to a lifesaving device without the enormous out of pocket cost. And the best part is how easy it is to use. There’s no assembly required, so you simply unwrap it and press it on the chest and stand back. No other AED operates this way and it is truly unique and novel! Although CardioThrive will be going to market using the standard bi-phasic waveform that delivers therapeutic shock at 140 joules of energy, its next-generation device will blow the competition out of the water. While conducting clinical trials at the Mayo Clinic, CardioThrive proved that the unique dual-paddle design of its device is able to create its patented multiphasic waveform that will deliver a life-saving shock at only 23 joules of energy. This has never been done before and no one else has this technology. Why is it so great? Because it means that the device will be the first ever that can be used on adults, small children, or even small pets without having to adjust the energy output settings. The clinical findings were published in PACE Medical Journal in February 2017. Shelley Savage commented, “The Mayo Clinic doctors were stunned that it actually worked! Needless to say, it was very exciting to be able to prove our theory in the lab that day.” Indeed, CardioThrive has the technology to make SCA a routinely survivable event – and it is looking forward to rapid expansion into every country on the planet. Its fully operational working prototypes to scale are nearly completed, and in mid-2022, it will be filing for regulatory approval in the US and in Europe. Company: CardioThrive Inc. Contact: Shelley Savage Email: shelleysavage@cardiothrive.com Website: www.cardiothrive.com
RkJQdWJsaXNoZXIy MTQxNTg3MQ==